Today, Enzymatica announced that the company's Annual Report for 2013 is available in Swedish as PDF at www.enzymatica.com and at Aktietorget’s website. It can also be read via the link below.
For more information, please contact:
Michael Edelborg Christensen, CEO, Enzymatica AB (publ) Phone: +46 768 14 41 66. E-mail: email@example.com
About Enzymatica AB (publ)
Enzymatica AB (publ) is a publicly traded biotechnology company focusing on research, development and sales of medical device products based on a patented enzyme technology. Enzymatica has several projects in the pipeline for diseases of the skin, throat and mucous membranes. Enzymatica has two registered medical device products, PeriZyme® Chewing Gum CE, against oral cavity diseases and ColdZyme® Mouth Spray CE against the common cold, the latter recently launched throughout the country.